公开(公告)号：US20240392257A1

公开(公告)日：2024-11-28

申请号：US18688756

申请日：2022-09-02

Applicant: Bavarian Nordic A/S

Inventor： Jürgen Hausmann ,  Markus Kalla ,  Marc Schweneker ,  Matthias Habjan

IPC: C12N7/00 ,  A61K39/00 ,  A61K39/285 ,  C12N15/113

Abstract: The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) comprising a series of miRNA target sequences arranged in a miRblock that is linked to a transgene, wherein each miRNA target sequence corresponds to a miRNA in a eukaryotic MVA producer cell. The present invention also relates to medical uses of the recombinant MVA.

公开(公告)号：US11884939B2

公开(公告)日：2024-01-30

申请号：US17565332

申请日：2021-12-29

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： Liang Deng ,  Stewart Shuman ,  Ning Yang ,  Taha Merghoub ,  Jedd Wolchok

IPC: C12N15/86 ,  C12N7/00 ,  C12N15/63 ,  C12N15/863 ,  A61K39/285 ,  A61P35/00 ,  A61K39/00

CPC classification number: C12N7/00 ,  A61K39/285 ,  A61P35/00 ,  C12N15/86 ,  A61K2039/525 ,  A61K2039/54 ,  A61K2039/55588 ,  C12N2710/24121 ,  C12N2710/24131 ,  C12N2710/24143

Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVAΔC7L and VACVΔC7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVAΔC7L or VACVΔC7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

公开(公告)号：US20230285548A1

公开(公告)日：2023-09-14

申请号：US18080639

申请日：2022-12-13

Applicant: Janssen Biotech, Inc.

Inventor： Patrick WILKINSON ,  Manuel Alejandro Sepulveda ,  Charles George Drake ,  Derick Siegel

IPC: A61K39/235 ,  A61K39/285 ,  A61K39/395 ,  A61K45/06

CPC classification number: A61K39/235 ,  A61K39/285 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505

Abstract: Disclosed herein are methods of treating or preventing a myeloproliferative disease, a cancer, or a cardiovascular disease, and methods of inducing an immune response, in a subject having a JAK2V617F substitution and/or a CALR exon 9 mutation.

公开(公告)号：US11723964B2

公开(公告)日：2023-08-15

申请号：US17693716

申请日：2022-03-14

Applicant: Bavarian Nordic A/S

Inventor： Hubertus Hochrein ,  Henning Lauterbach ,  José Medina Echeverz ,  Matthias Habjan

IPC: A61K39/285 ,  A61K39/00

CPC classification number: A61K39/001106 ,  A61K39/001152 ,  A61K39/285 ,  A61K2039/505 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/6075 ,  A61K2039/70

Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.

公开(公告)号：US11541114B2

公开(公告)日：2023-01-03

申请号：US16834359

申请日：2020-03-30

Applicant: CITY OF HOPE

Inventor： Don Diamond ,  Zhongde Wang

IPC: A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.

公开(公告)号：US20220249636A1

公开(公告)日：2022-08-11

申请号：US17693716

申请日：2022-03-14

Applicant: Bavarian Nordic A/S

Inventor： Hubertus HOCHREIN ,  Henning LAUTERBACH ,  José MEDINA ECHEVERZ ,  Matthias HABJAN

IPC: A61K39/00 ,  A61K39/285

Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.

公开(公告)号：US20210401974A1

公开(公告)日：2021-12-30

申请号：US17289267

申请日：2019-10-31

Applicant: Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Inventor： Markus Radsak ,  Julian Sohl ,  Michael Stassen ,  Ann-Kathrin Hartmann

IPC: A61K39/285 ,  A61K31/122 ,  A61K31/4745 ,  A61K31/708 ,  A61K38/16 ,  A61K31/713 ,  A61K31/711 ,  A61K9/00 ,  A61K39/39 ,  A61P31/20

Abstract: Pharmaceutical compositions and pharmaceutical combination preparations. The pharmaceutical compositions and the pharmaceutical combination preparations comprise at least one oxidative stressor selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The pharmaceutical compositions or combination preparations may be used in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations may find use for topical application on the skin of a human or animal body.

公开(公告)号：US11197920B2

公开(公告)日：2021-12-14

申请号：US16302295

申请日：2017-05-18

Applicant: Oxford University Innovation Limited

Inventor： Arturo Reyes-Sandoval

IPC: A61K39/015 ,  A61K39/285 ,  A61K39/29 ,  A61K39/235 ,  A61P33/06 ,  A61K39/39 ,  A61K39/00

Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.

公开(公告)号：US11052147B2

公开(公告)日：2021-07-06

申请号：US16612561

申请日：2018-05-15

Applicant: Janssen Vaccines & Prevention B.V. ,  Bavarian Nordic A/S

Inventor： Ahmad Shakeb Sediq ,  Wouter Frank Tonnis ,  Martinus Anne Hobbe Capelle

IPC: A61K39/00 ,  A61K39/12 ,  C12N15/86 ,  C12N7/00 ,  A61K39/275 ,  A61K39/285 ,  A61P31/04 ,  A61K47/20

Abstract: Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.

公开(公告)号：US20210187100A1

公开(公告)日：2021-06-24

申请号：US17273977

申请日：2019-09-06

Applicant: Bavarian Nordic A/S

Inventor： Katrine Kjaer ,  Kerstin Mammeri

IPC: A61K39/285 ,  C12N7/00

Abstract: The present invention provides storage optimized aqueous compositions comprising a poxvirus suitable as poxvirus vaccine and pharmaceutical compositions, in particular liquid compositions or liquid frozen compositions, and methods of making them.